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Abstract
Background: Sedentary lifestyle is associated with coronary artery disease but even shorter periods of physical
inactivity may increase cardiovascular risk. Cystatin C is independently associated with cardiovascular disease and
our objective was to investigate the relation between this novel biomarker and standardized bed rest. Research of
immobilization physiology in humans is challenging because good biological models are in short supply. From the
Women International Space simulation for Exploration study (WISE) we studied markers of atherosclerosis and
kidney function, including cystatin C, in a standardized bed rest study on healthy volunteers. Fifteen healthy female
volunteers participated in a 20-day ambulatory control period followed by 60 days of bed rest in head-down tilt
position (-6°) 24 h a day, finalized by 20 days of recovery. The subjects were randomized into two groups during
bed rest: a control group (n = 8) that remained physically inactive and an exercise group (n = 7) that participated
in both supine resistance and aerobic exercise training.
Results: Compared to baseline values there was a statistically significant increase in cystatin C in both groups after
bed rest (P < 0.001). Glomerular filtration rate (GFR), calculated by both cystatin C and Cockcroft-Gault equation,
decreased after bed rest while there were no differences in creatinine or creatine kinase levels. CRP did not change
during bed rest in the exercise group, but there was an increase of CRP in the control group during recovery
compared to both the baseline and the bed rest periods. The apo-B/apo-Ai ratio increased during bed rest and
decreased again in the recovery period. Subjects experienced a small but statistically significant reduction in
weight during bed rest and compared to baseline weights remained lower at day 8 of recovery.
Conclusion: During and following prolonged standardized bed rest the concentrations of several clinically relevant
cardiovascular risk markers change.
Background
Sedentary lifestyle is associated with inflammation in
population-based studies [1,2] and increases cardiovas-
cular risk [3].
Bed rest causes muscle atrophy, which in turn leads to
lower creatinine levels and decreased glomerular filtra-
tion rate (GFR), when calculated by the Modification of
Diet in Renal Disease (MDRD) formula or Cockcroft-
Gault formula dependant on creatinine [4]. Cystatin C is
also a marker of GFR but is unaffected by muscle mass.
However, age, sex, weight, smoking and high
concentrations of CRP affect the plasma level of cystatin
C [5]. Because bed rest and cystatin C levels are both
cardiovascular risk factors we found it of interest to
investigate how cystatin C, together with other risk mar-
kers, are affected by prolonged standardized bed rest.
It has been proposed that elevated cystatin C levels
are directly correlated to both inflammation and athero-
sclerosis [6]. High cystatin C levels are independently
associated with cardiovascular risk factors such as BMI,
low HDL cholesterol and smoking even in patients with-
out chronic kidney disease or microalbuminuria [7].
Cystatin C is independently associated with cardiovascu-
lar disease after adjustment for major cardiovascular risk
factors [8]. Jernberg et al. demonstrated an association
between cystatin C level and mortality in patients with
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ary syndrome [9].
Research of immobilisation and human physiology is
challenging because good biological models are in short
supply. Interpretation of biological samples in hospita-
lized patients may be biased by various disease states,
surgical and other invasive procedures and non-standar-
dized bed rest regimens. In collaboration with the
Women International Space simulation for Exploration
study (WISE) conducted in 2005 [10] we studied kidney
function and atherosclerosis/inflammation markers in a
two-month bed rest study on healthy volunteers
enabling research on the physiopathology of
immobilization.
Methods
Study design
Sixteen healthy female volunteers participated in a 60-
day bed rest study. All were non-smokers, free of any
clinical/biomedical sicknesses and had not taken any
contraceptive pills 3 months prior to the study. An addi-
tional inclusion criterion was that the participants were
required to exercise 30 minutes per day (moderate activ-
ity as structured exercise or activities in daily living)
prior to the study.
A 20-day ambulatory control period was followed by
60 days of bed rest in head-down tilt position (-6°) 24 h
a day and the study was finalised by a 20 day recovery
period (Figure 1). Baseline data collection was
performed in the ambulatory control period. The sub-
jects were randomized into two groups (n = 8, each)
during bed rest: a control group that remained physi-
cally inactive and an exercise group that participated in
both supine resistance and aerobic exercise training. Fif-
teen of the participants gave informed consent to parti-
cipate in our study.
The resistance training included 19 sessions of 45
minutes training on a flywheel ergometer (including 10
min of warm up). The aerobic training was designed as
29 sessions using a specially designed vertical treadmill.
Each session lasted 50 ± 2 min at varying intensities
between 40 and 80% of pre-bed rest maximum oxygen
uptake. All sessions were equally distributed during the
entire bed rest period. The detailed protocol of the
WISE experiment and the training sessions are
described in detail in previous reports [10].
Laboratory analysis
Blood samples were collected in heparin-containing
tubes at baseline (five days before bed rest), after 44
days of bed rest and 8 days into the recovery period
(Figure 1). All samples were taken within 15 min after
breakfast. The samples were centrifuged immediately at
3000 rpm for 10 min, and plasma was frozen within 30
min and stored in aliquots at -80°C.
Plasma apolipoprotein A1 (reagent: 9D92-01), apolipo-
protein B (reagent: 9D92-01), creatine kinase (reagent:
7D63-20), creatinine (reagent: 8L24-01), C-reactive
Figure 1 Overview of the bed rest study. A 20-day ambulatory control period was followed by 60 days of bed rest in head-down tilt position
(-6°) and the study was finalised by 20 days recovery period.
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Page 2 of 9protein (reagent: 6K2601) and cystatin C (Cyc-C)
(reagent: 1014; Gentian, Moss, Norway) were analyzed
on an Architect Ci8200 (Abbott Laboratories, Abbott
Park, IL, USA) and reported using SI units. The total
analytical imprecision of the assays were: 1.8% at 0.68 g/
L and 1.2% at 2.0 g/L for apolipoprotein A, 4.5% at 0.47
g/L and 2.4% at 1.68 g/L for apolipoprotein A, 0.7% at
2.8 μkat/L and 0.8% at 13 μkat/L for creatine kinase,
4.8% at 70 mmol/L and 4.8% at 94 mmol/L for creati-
nine, 0.8% at 8 mg/L for C-reactive protein and 1.7% at
0.77 mg/L and 1.1% at 1.25 mg/L for cystatin C.
GFR was calculated using the Cockcroft-Gault for-
mula, which estimates GFR in mL/min.
GFR =
(140 − Age) × Mass

in kilograms

× constant
Serum creatinine

in micromol/L
 ,
where constant is 1.23 for men and 1.04 for women.
We used a cystatin C immunoassay from Gentian
(Gentian, Moss, Norway) on Architect ci8200 (Abbott
Laboratories, Abbott Park, Ill., USA) to calculate GFR in
mL/min/1.73 m
2. The formula for calculating GFR with
cystatin C is eGFR (mL/min/1.73 m2) = 79.901* (cysta-
tin C value in mg/L)
-1.4389 [11].
Statistical analysis
Statistical analysis was performed using SigmaStat 3.5
software (Systat, San Jose, Ca). Blood sample results
were compared by a two way repeated measures analysis
of variance and a p-value of < 0.05 was considered sta-
tistically significant.
Results
Baseline characteristics of the volunteers: age, height,
weight, body mass index (BMI) and blood pressure are
summarized in table 1. Weight decreased in both groups
after 44 days of bed rest and the weight reduction was
still statistically significant in the recovery period when
compared to baseline. After 8 days of bed rest there was
a small but significant weight increase in the control
group, but not in the exercise group, compared to the
bed rest period.
C R Pd i dn o tc h a n g ed u r i n gt h eb e dr e s tp e r i o di nt h e
exercise group, but there was a statistically significant
increase in CRP in the control group in the recovery
period compared to both the control period (46%, p-
v a l u e0 . 0 0 8 )a n dt h eb e dr e s tp e r i o d( 3 9 % ,p - v a l u e
0.021) (Figure 2). During the recovery period there was
a statistically significant difference in CRP between
groups (56%, p-value 0.025). There was no difference in
creatinine and creatine kinase levels (Figure 3 and 4).
There was a statistically significant increase in cystatin
C in both groups 8 days after bed rest compared to
baseline (16%, p-value < 0.0001) and 44 days of bed rest
(12%, p-value < 0.0004) (Figure 5). GFR calculated with
cystatin C decreased significantly in both groups after
bed rest completion (Figure 6) compared to baseline
(26% decrease, p-value < 0.0001) and 44 days of bed rest
(19%decrease, p-value 0.0002). Similarly GFR calculated
with the Cockcroft-Gault formula decreased after bed
rest completion (Figure 7) compared to baseline (11%,
p - v a l u e0 . 0 0 1 )a n d4 4d a y so fb e dr e s t( 2 % ,p - v a l u e
0.005).
The apo-B/apo-Ai ratio increased after 44 days of bed
rest (15%, p-value < 0.0001) and decreased again 8 days
into the recovery period (25%, p-value < 0.0001) (Figure
8).
Discussion
In this study we measured the effect of bed rest on
plasma concentrations of cystatin C, which is an emer-
ging marker of cardiovascular disease. We also mea-
sured traditional markers of inflammation and kidney
function. Eight days after a bed rest period of 60 days
was completed cystatin C levels increased and GFR
Table 1 Baseline data of age, height, weight, BMI, systolic and diastolic blood pressure.
Baseline After 44 d of bed rest After 8 days of recovery
Control Exercise Control Exercise Control Exercise
N 8 78787
Age (yr) 34 ± 4 34 ± 3 34 ± 4 34 ± 3 34 ± 4 34 ± 3
Height (m) 1.63 ± 0.06 1.67 ± 0.05 1.63 ± 0.06 1.67 ± 0.05 1.63 ± 0.06 1.67 ± 0.05
Weight (kg) 55.6 ± 3.9 59.3 ± 2.7 52.6 ± 4.0 *# 56.5 ± 5.7 * 53.6 ± 4.2 * 56.4 ± 4.8 *
BMI (kg/m
2) 21 ± 1.2 21.3 ± 1.6 19.9 ± 1.2 *# 20.4 ± 1.6 * 20.2 ± 1.3 * 20.3 ± 1.6 *
Systolic blood pressure (mmHg) 97 ± 8 96 ± 8 98 ± 11 104 ± 10 96 ± 14 101 ± 8
Diastolic blood pressure (mmHg) 59 ± 6 55 ± 8 63 ± 11 * 64 ± 7 * 60 ± 13 60 ± 10
Weight decreased during bed rest in both groups. The exercise group had not gained weight 8 days into the recovery period, but the control group gained
some weight.
* = statistically significant difference compared to baseline
# = statistically significant difference compared to recovery period
There was no statistically significant difference between the groups.
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Figure 2 CRP levels during bed rest study. CRP did not change during the bed rest period in the exercise group, but there was a statistically
significant increase in CRP in the control group in the recovery period compared to both the control period and the bed rest period.
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Figure 3 Creatinine levels during bed rest study. There was no difference in creatinine levels.
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Figure 4 Creatine kinase levels during bed rest study. There was no difference in creatine kinase levels.
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Figure 5 Cystatin C levels during bed rest study. There was a statistically significant increase in cystatin C after the bed rest completion.
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Figure 6 GFR levels during bed rest study. There was a statistically significant decrease in GFR, calculated with cystatin C in both groups after
the bed rest completion.
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Figure 7 GFR levels during bed rest study. There was a statistically significant decrease in GFR, calculated with the Cockcroft-Gault formula in
both groups after the bed rest completion.
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Page 6 of 9decreased and for GFR this was independent of calcula-
tion method.
Bed rest is probably the single most applied therapy
for hospitalized patients no matter the underlying dis-
ease. It is therefore of great importance to understand
the pathophysiological changes during immobilization as
it may influence treatment. The growing problem of
“sedentary lifestyle” could also be considered as a global
immobilisation experiment. Future trips to Mars require
further information of the effect of immobilization to
the human body.
Patients with elevated levels of cystatin C are at
higher risk of developing cardiovascular diseases [8,9].
Low glomerular filtration rate is a risk factor for cardi-
ovascular mortality, independent of other cardiovascu-
lar risk factors [12]. Peralta el al discussed the
probability that cystatin C might be a better parameter
for identifying patients with chronic kidney disease at
risk of developing cardiovascular complications than a
creatinine-based equation [13]. Other researchers
found that elderly people with the highest quintile of
cystatin C (1.29 mg/i) have a significantly elevated risk
of death from cardiovascular causes, myocardial infarc-
tion, and stroke after multivariate adjustment [14].
Cystatin C is linearly associated with cardiovascular
mortality, but creatinine on the other hand predicts
worse outcome only in patients with severe kidney
dysfunction [15].
It has been described that high cystatin C levels corre-
late to an extensively increased risk of cardiovascular
events in persons who do not meet the criterion of
eGRF ≤ 60 mL/min/1.73 m2, a definition of chronic kid-
ney disease [16]. High cystatin C levels have been found
to be associated with elevated levels of CRP and [5,17]
and other inflammatory mar k e r ss u c ha sI L - 6 ,t u m o u r
necrosis factor alpha (TNF-a), and two soluble TNF-a
receptors, even with creatinine-based eGFR ≥ 60 mL/
min/1.73 m2 [18]. How non-renal factors influence
cystatin C concentrations need further research.
In our study CRP was elevated after bed rest in the
non-exercise group. Our finding might reflect that bed
rest increases inflammatory activity, which in turn
advances the atherosclerotic process leading to
enhanced risk of CVD as well as elevated cystatin C
levels by atherosclerosis in the kidneys and thereby a
decreased glomerular filtration rate. In a recent study of
overweight/obese postmenopausal women practising
physical activity, it was shown that women with the
highest tertile of physical activity energy expenditure
had lower concentrations of hsCRP after adjustment for
fat mass [19]. This can give an explanation to the differ-
ence in CRP between the control group and the exercise
group in our study.
Cystatin C also has a different role in relation to
inflammation/atherosclerosis. Inflammatory cytokines
associated with atherosclerosis stimulate the production
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Figure 8 Lipid levels during bed rest study. The apo-B/apo-Ai ratio increased after 44 days of bed rest and decreased again 8 days into the
recovery period.
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Page 7 of 9of lysosomal cathepsins and increase the plasma concen-
tration of cystatin C. Cystatin C is a cathepsin inhibitor
and might therefore play a roll in counterbalancing a
potentially destructive greater elastolytic activity [20].
Mice deficient in cystatin C have increased elastic
lamina degradation and greater atherosclerotic plaque
formation. Studies have shown that both cathepsins and
their inhibitor cystatin C could act either pro- or anti-
atherogenic in the different stages of atherosclerosis
[21]. This role of cystatin C probably plays a lesser part
in our study.
A limitation to our study is that the blood samples
were taken in 2005 and analysed five years later. This
might have influenced our results. A recent study how-
ever, has shown that when using the Gentian method
the cystatin C levels were stable when comparing blood
samples over four years of time [22].
All samples were analyzed in a single batch and in a
random mode with the same reagent batch and the
same calibration on a single instrument. The instrument
has a high assay capacity so the time interval between
first and last assay were less than 30 min. This in com-
bination with the low assay CVs makes it unlikely that
the differences in this study are due to variation in the
assay or sample evaporation during the assay. Our find-
ings were done in women only and the groups were
relatively small. Knight et al. found in a cross-sectional
study that male gender was independently associated
with higher serum cystatin C after adjusting for creati-
nine clearance. Older age, greater height and weight
have a similar effect. Previously, serum cystatin C levels
have been found to correlate somewhat with weight [5].
In our study there was a statistically significant weight
reduction in both groups after 44 days of bed rest and
in the recovery period compared to baseline. According
to Knight et al. because of weight loss a reduction in
cystatin C levels could have been expected. In verte-
brates both metabolic rate and glomerular filtration rate
are positively correlated to body size [23]. However, we
found the opposite - an increase in cystatin C levels.
This could indicate that cystatin C is a marker of other
physiological processes than kidney function. Knight et
al. showed that high CRP levels are independently asso-
ciated with increased cystatin C levels after adjustment
for creatinine clearance. Cystatin C can also be a bio-
marker for inflammation [24,25]. In another substudy of
WISE it was shown that bed rest causes both mechanis-
tic and functional impairment of endothelial function
[26]. These results could serve as a possible explanation
for the cystatin C findings in our study - because early
changes in endothelial function are part of the patho-
genesis of atherosclerosis.
The decrease in GFR calculated with the Cockcroft-
Gault formula can be explained by a combination of
weight reduction and stable creatinine values. Weight
r e d u c t i o ni nt h ec o n t r o lg r o u pw a sm o s tl i k e l yd u et o
muscle atrophy and stable fat mass. Unexpectedly, Ber-
gouignan et al. showed that the desire to eat was
reduced in the exercise group - leading to a negative
energy balance and a decrease in fat mass [27]. It is a
limitation to our study that a golden standard measure-
ment, as e.g. iohexol clearance, was not used. We did,
however, use two different methods to calculate GFR,
both dependent (the Cockcroft-Gault formula) and inde-
pendent of weight (cystatin C) and the findings were
identical - a decrease in GFR after bed rest. In a recent
cross sectional study of persons with early stages of
chronic kidney disease, light and total physical activity
were positively correlated to kidney function when mea-
sured by MDRD. This relationship lost statistical signifi-
cance after adjustment for BMI, cholesterol, CRP and
mean arterial blood pressure. Increased physical activity
may reduce the progression of chronic kidney disease by
decreasing oxidative stress and inflammation and redu-
cing blood pressure besides the positive effect of weight
loss [28]. Conceivably decreased physical activity, in our
study bed rest, has the opposite effect with an increase
in oxidative stress and inflammation.
We cannot explain why the changes were seen first
after the bed rest study was completed and not during
bed rest. The effect could be due to the change from
resting to standing position as it has previously been
shown that body position per se influences renal perfu-
sion [29]. Further studies are required to determine the
mechanism of the effect of bed rest on cystatin C as
well as other cardiovascular risk markers.
Conclusion
In conclusion, cystatin C increased and cystatin C esti-
mated GFR decreased in healthy female volunteers after
a standardized bed rest period of 60 days. As cystatin C
is a cardiovascular risk marker, this study may implicate
that longer time periods of immobilization augment the
risk of atherosclerosis. This is however only a hypoth-
esis. Further studies are warranted to explore the role of
cystatin C as a link between inactivity and cardiovascu-
lar risk.
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